J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its Crohn’s disease treatment Tremfya sustained or improved fistula remission through 48 weeks in a Phase 3 clinical trial, …
J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks Read More